GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: Lessons from the 4B and Get-Goal DUO 2 trials

Diabetes and Metabolism

Volumn 41, Issue 6, 2015, Pages 6S16-6S20

  Porcellati, F ^a   Lucidi, P ^a   Bolli, G B ^a   Fanelli, C G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Basal insulin; Exenatide; GLP 1 receptor agonists; Lixisenatide

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; LIXISENATIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK REDUCTION; WEIGHT REDUCTION; AGONISTS; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PATIENT CARE PLANNING; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN GLARGINE; PATIENT CARE PLANNING; PEPTIDES; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOMS;

EID: 84953215244     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(16)30004-0     Document Type: Article

References (23)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
2. Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Lepore M, et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999, 22:795-800.
3. Owens DR, Monnier L, Bolli GB Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes Metab 2013, 39:485-496.
4. Meier JJ GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 8:728-742.
5. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:2719-2725.
6. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993, 36:857-862.
7. Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, Vilsbøll T, Knop FK Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013, 56:965-972.
8. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008, 57:1340-1348.
9. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011 18, 154:103-112.
10. Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013, 36:2489-2496.
11. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, et al. J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013, 36:2497-2503.
12. Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, 4B Study Group, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014, 37:2763-2773.
13. Rosenstock J, Hanefeldt M, Gentile S, Aronson R, Tinahones FJ, Guerci B, et al. Advancing Basal Insulin Glargine with Prandial Lixisenatide QD vs. Insulin Glulisine QD or TID in T2DM: The GetGoal-Duo2 Evidence-Based Trial (NCT01768559). 75th Congress of the American Diabetes Association, Boston June 2015. Poster 107-LB (last accessed: October 15th, 2015). https://ada.scientificposters.com/epsSearchADA.cfm.
14. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006, 49:442-451.
15. Yki-Järvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs (EDITION 2 randomised 12-month trial including 6-month extension). Diab Obes Metab 2015; Jul 14, [Epub ahead of print].
16. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA, Orals Plus Apidra and LANTUS (OPAL) study group Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008, 10:1178-1185.
17. Del Prato S, Nicolucci A, Lovagnini-Scher AC, Turco S, Leotta S, Vespasiani G, ELEONOR Study Group Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. Diabetes Technol Ther 2012, 14:175-182.
18. Menge BA, Kapitza C, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester HV, et al. Impact of baseline gastric emptying on effects of lixisenatide and liraglutide in type 2 diabetes mellitus (T2DM) as add-on to insulin glargine. Diabetologia 2014, 57(Suppl1):S38.
19. DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Liraglutide-Detemir Study Group, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012, 35:1446-1454.
20. Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, BEGIN: VICTOZA ADD-ON (NN1250-3948) study group, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014, 16:636-644.
21. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
22. Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahrén B, Chow FC, Harmony 6 Study Group, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care 2014, 37:2317-2325.
23. Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015, 385:2057-2066.